Biotalys Shares Surge 18% Following Key US Approval

Approval of EVOCA in Florida, Catalyst for the Session

Today's movement is explained by the announcement made this Monday through a press release of the first US approval of the biofungicide EVOCA, the company's flagship product. The state of Florida has registered this biocontrol based on the proprietary AGROBODY technology, marking a decisive regulatory step for Biotalys' entry into the US market. Florida, being the leading national producer of many fruit crops, represents a significant commercial outlet for this type of biological solution.
Over the past week, the stock now shows a gain of 23.77%, offsetting some of the underperformance recorded over the past three months (-13.21%). The publication of the annual results, expected on Wednesday, April 29, will be the next major event for investors, followed by the general meeting scheduled for May 29.

Stock Still in a Technical Fragility Zone Despite the Rebound

Despite the magnitude of today's rebound, Biotalys' share price remains below its 50-day moving average (€2.91) and significantly below the 200-day average (€4.14), indicating an ongoing negative underlying trend. The RSI, at 13, is in a territory of extreme overselling, a level rarely observed, signaling that the stock was significantly depressed before this session.
In the Bollinger Bands, the price is now in the upper part of the channel, at 74% of the range defined between €1.86 and €3.07, whereas it was near the lower bound the previous week. The nearest resistance threshold is at €2.96, a level the stock has not yet crossed during the session. The beta of 0.14 also reflects a very low correlation with major indices, meaning that Biotalys' variations are primarily driven by company-specific catalysts rather than the general macroeconomic context.